Genomic profiling and PD-L1 expression of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CIBI308ALTER-C201 trial

被引：0
|
作者：
Xu, Qin [1 ]
Chen, Chuanben [2 ]
Sun, Yang [2 ]
Huang, Zhangzhou [2 ]
Lin, Yibin [2 ]
Liu, Jing [2 ]
Li, Li [2 ]
Li, Zirong [3 ]
Pan, Junping [2 ]
Chen, Ying [2 ]
机构：
[1] Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Fuzhou, Peoples R China
[2] Fujian Canc Hosp, Fuzhou, Peoples R China
[3] Fujian Med Univ, Longyan Affiliated Hosp 1, Fuzhou, Peoples R China
来源：
GYNECOLOGIC ONCOLOGY | 2022年 / 166卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
035
引用
收藏
页码：S24 / S25
页数：2
相关论文
共 26 条
  • [21] Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
    Chen, Wei
    Chen, Jiayi
    Zhang, Lin
    Cheng, Sheng
    Yu, Junxian
    BMC CANCER, 2023, 23 (01)
  • [22] Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
    Wei Chen
    Jiayi Chen
    Lin Zhang
    Sheng Cheng
    Junxian Yu
    BMC Cancer, 23
  • [23] Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores
    Lea, Dordi
    Zaharia, Claudia
    Soreide, Kjetil
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 38
  • [24] Impact of tislelizumab plus chemotherapy versus placebo plus chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial.
    Yoon, Harry H.
    Xu, Jianming
    Kato, Ken
    Pan, Yueyin
    Park, Sook Ryun
    Shen, Lin
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Barnes, Frederick
    Sun, Tianmo
    Barnes, Gisoo
    Victor, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 366 - 366
  • [25] Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P plus C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): Primary analysis from multicenter single arm phase II study (Evolution trial; WJOG11819L).
    Hata, Akito
    Ninomaru, Taira
    Okada, Hideaki
    Kogure, Yoshihito
    Oki, Masahide
    Katakami, Nobuyuki
    Kijima, Takashi
    Yokoyama, Toshihide
    Matsumoto, Hirotaka
    Sato, Yuki
    Kato, Terufumi
    Sugawara, Shunichi
    Sawada, Takeshi
    Yoshimura, Kenichi
    Seto, Takashi
    Nakagawa, Kazuhiko
    Okamoto, Isamu
    Yamamoto, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8050 - LBA8050
  • [26] Radiation therapy (RT)-free pembrolizumab plus chemotherapy (P plus C) for PD-L1 TPS ≥50% locally advanced non-small cell lung cancer (LA-NSCLC): An early report analyzing depth of response from multicenter single arm phase II study (Evolution trial: WJOG11819L).
    Hata, Akito
    Ninomaru, Taira
    Okada, Hideaki
    Kogure, Yoshihito
    Oki, Masahide
    Katakami, Nobuyuki
    Kijima, Takashi
    Yokoyama, Toshihide
    Matsumoto, Hirotaka
    Sato, Yuki
    Kato, Terufumi
    Sugawara, Shunichi
    Sawada, Takeshi
    Yoshimura, Kenichi
    Seto, Takashi
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
123